Tag:

antibodies

Latest Headlines

Latest Headlines

Roche brings an Alzheimer's drug back from the brink with another PhIII endeavor

Roche is resuscitating development for gantenerumab, an Alzheimer's treatment that flamed out in Phase III late last year, as recent clinical results have emboldened the company to launch new studies.

Agenus bags cancer antibodies in $44M deal

Lexington, MA-based Agenus has bagged the rights to some cancer-related antibodies from Italy's Diatheva s.r.l., agreeing to fork over up to $44 million in milestones for a successful development program.

Lilly and Biogen prep make-or-break Alzheimer's data amid an amyloid renaissance

Biogen and Eli Lilly, two drugmakers making big bets in Alzheimer's disease, are set to present clinical data on a pair of much-scrutinized projects with potential to change the industry's approach to the field.

AC Immune snags milestone as Genentech picks Alzheimer's asset to advance to clinic

AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.

Dyax gets an FDA 'breakthrough' tag for its rare disease drug

The FDA has conferred its coveted breakthrough-therapy designation to Dyax's lead pipeline asset, an antibody designed to treat flare-ups of the rare hereditary angioedema.

Antibody 'cocktail' looks promising against deadly Marburg virus

In a recent study, scientists at The Scripps Research Institute have characterized new antibodies that protect against the ebolavirus' sinister relative--the Marburg virus.

Kite taps Adimab to lend a hand in CAR-T R&D

Kite Pharma, at work on therapies that use the immune system to fight cancer, paired up with Adimab to expand its R&D efforts.

GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers

A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.

Ablynx adds Genzyme to roster of big-name collaborators

Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.

Third Rock's Jounce bags $56M to hit the gas in immuno-oncology

While Merck and Bristol-Myers Squibb grab global headlines with treatments designed to make it harder for cancer to hide from the immune system, Cambridge, MA's Jounce Therapeutics is coming at it from the other end, crafting a therapy that revs up the body's natural defenses to attack tumors. And the promise of that idea helped the biotech rope in a massive $56 million B round, cash that will help get its top prospect into clinical trials.